Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Common Equity (2016 - 2025)

Historic Common Equity for Neuroone Medical Technologies (NMTC) over the last 14 years, with Q4 2025 value amounting to $6.4 million.

  • Neuroone Medical Technologies' Common Equity rose 11810.18% to $6.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.4 million, marking a year-over-year increase of 11810.18%. This contributed to the annual value of $7.1 million for FY2025, which is 76039.05% up from last year.
  • Neuroone Medical Technologies' Common Equity amounted to $6.4 million in Q4 2025, which was up 11810.18% from $7.1 million recorded in Q3 2025.
  • Neuroone Medical Technologies' Common Equity's 5-year high stood at $15.9 million during Q4 2021, with a 5-year trough of $822013.0 in Q3 2024.
  • Moreover, its 5-year median value for Common Equity was $6.5 million (2021), whereas its average is $6.9 million.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 103253.32% in 2021, then tumbled by 8684.65% in 2024.
  • Over the past 5 years, Neuroone Medical Technologies' Common Equity (Quarter) stood at $15.9 million in 2021, then plummeted by 48.76% to $8.2 million in 2022, then crashed by 45.93% to $4.4 million in 2023, then crashed by 33.56% to $2.9 million in 2024, then surged by 118.1% to $6.4 million in 2025.
  • Its last three reported values are $6.4 million in Q4 2025, $7.1 million for Q3 2025, and $8.2 million during Q2 2025.